1994
DOI: 10.1016/0168-3659(94)90117-1
|View full text |Cite
|
Sign up to set email alerts
|

Approaches to targetted photodynamic tumor therapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
16
0

Year Published

1995
1995
2012
2012

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 23 publications
(16 citation statements)
references
References 31 publications
0
16
0
Order By: Relevance
“…Binding of synthetic porphyrins to proteins such as human serum albumin, BSA and low‐density lipoproteins has been investigated by several groups [1–3]. Recently porphyrins have been used as photosensitizers in photodynamic therapy (PDT), a new approach developed for the treatment of cancer [4,5]. In PDT, when excited by light of appropriate wavelength, the porphyrin photosensitizers interact with molecular oxygen and convert it to the triplet form, which then reacts with the surrounding tissue and leads to cell death.…”
mentioning
confidence: 99%
“…Binding of synthetic porphyrins to proteins such as human serum albumin, BSA and low‐density lipoproteins has been investigated by several groups [1–3]. Recently porphyrins have been used as photosensitizers in photodynamic therapy (PDT), a new approach developed for the treatment of cancer [4,5]. In PDT, when excited by light of appropriate wavelength, the porphyrin photosensitizers interact with molecular oxygen and convert it to the triplet form, which then reacts with the surrounding tissue and leads to cell death.…”
mentioning
confidence: 99%
“…However, the selectivity of porphyrin compounds towards tumour cells is not always sufficient for PDT to be efficacious. Recently, targeted PDT molecules have been invented by use of special molecules (antibodies or hormones) with photosensitizers aiming to improve their selectivity for tumors (18).…”
Section: Resultsmentioning
confidence: 99%
“…The first concerns the development of PDT systems to enhance the efficiency of delivery to target cells. Most (Hamblin and Newman, 1994;Klyashchitsky et al, 1994;Dolmans et al, 2003), but not all (Gijsens et al, 2002;Sharman et al, 2004) targeted PDT studies have used monoclonal antibodies as the address moiety. As the use of antibodies poses several practical limitations (Rihova, 1998), an alternate approach is to target a Tf -Ps conjugate to Tf receptors that are overexpressed on tumour cells (Faulk et al, 1980;Cavanaugh, 2002).…”
Section: Discussionmentioning
confidence: 99%
“…First, whereas Pss tend to accumulate in tumour tissue, their clinical use is often associated with side effects such as cutaneous photosensitivity (Vrouenraets et al, 2003;Sharman et al, 2004). To overcome this problem investigators have covalently linked the Ps to carrier molecules so as to localise the PDT effect (Klyashchitsky et al, 1994;Vrouenraets et al, 2003). One attractive carrier protein -receptor system for this purpose utilises the high-affinity interaction between the iron-transporter transferrin (Tf) and its cell-surface receptor (TfR, CD71).…”
mentioning
confidence: 99%